Evidence map›Paper›PMID 28284258›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2017

R F Armenta, K M Collins, S A Strathdee, M A Bulterys, F Munoz, J Cuevas-Mota, P Chiles, R S Garfein

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

R F ArmentaDivision of Epidemiology, Department of Family Medicine and Public Health, University of California San Diego, San Diego.
K M CollinsDivision of Global Public Health, Department of Medicine, University of California San Diego, San Diego.
S A StrathdeeDivision of Global Public Health, Department of Medicine, University of California San Diego, San Diego.
M A BulterysDivision of Global Public Health, Department of Medicine, University of California San Diego, San Diego.
F MunozDivision of Global Public Health, Department of Medicine, University of California San Diego, San Diego.
J Cuevas-MotaDivision of Global Public Health, Department of Medicine, University of California San Diego, San Diego.
P ChilesDivision of Pulmonology, Critical Care and Sleep Medicine, Department of Medicine, University of California San Diego, San Diego, California, USA.
R S GarfeinDivision of Global Public Health, Department of Medicine, University of California San Diego, San Diego.
University of California, San Diego · USUniversity of California System · US

Funding

Training Program in Substance Use, HIV and Related InfectionsT32DA023356 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Natasha Martin, Steffanie A Strathdee · 2007 to 2026
$7.8M
Impact of Drug Policy Reform on the HIV Risk Environment among IDUs in TijuanaR37DA019829 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2010 to 2019
$6.7M
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUsR01DA031074 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARFEIN, RICHARD S · 2011 to 2015
$3.2M
NIDA NIH HHS R01 DA031074NIDA NIH HHS R37 DA019829NIDA NIH HHS T32 DA023356
6 · The paper itself

Abstract

backgroundPersons who inject drugs (PWID) might be at increased risk for Mycobacterium tuberculosis infection and reactivation of latent tuberculous infection (LTBI) due to their injection drug use.

objectivesTo determine prevalence and correlates of M. tuberculosis infection among PWID in San Diego, California, USA.

methodsPWID aged 18 years underwent standardized interviews and serologic testing using an interferon-gamma release assay (IGRA) for LTBI and rapid point-of-care assays for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections. Independent correlates of M. tuberculosis infection were identified using multivariable log-binomial regression.

resultsA total of 500 participants met the eligibility criteria. The mean age was 43.2 years (standard deviation 11.6); most subjects were White (52%) or Hispanic (30.8%), and male (75%). Overall, 86.7% reported having ever traveled to Mexico. Prevalence of M. tuberculosis infection was 23.6%; 0.8% were co-infected with HIV and 81.7% were co-infected with HCV. Almost all participants (95%) had been previously tested for M. tuberculosis; 7.6% had been previously told they were infected. M. tuberculosis infection was independently associated with being Hispanic, having longer injection histories, testing HCV-positive, and correctly reporting that people with 'sleeping' TB cannot infect others.

conclusionsStrategies are needed to increase awareness about and treatment for M. tuberculosis infection among PWID in the US/Mexico border region.

Indexed as

AdolescentAdultAgedAged, 80 and overCaliforniaCoinfectionCross-Sectional StudiesFemaleHepatitis CHIV InfectionsHumansInterferon-gamma Release TestsLatent TuberculosisMaleMiddle AgedPoint-of-Care Systems

Identifiers

PMID28284258
PMCPMC6352726
OpenAlexW2752109414

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.